LGBCL: phase 2 study of intensified rituximab induction and maintenance

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • In patients with newly diagnosed or rituximab-naive low-grade B-cell lymphoma (LGBCL), intensified rituximab (Rituxan) induction and maintenance delivered tolerable, impressive efficacy

Why this matters

  • Risk scoring systems such as Sokal and European Treatment and Outcome Stud...